IDA: Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy
Study Details
Study Description
Brief Summary
Non-small-cell lung cancer (NSCLC) accounts for a majority (approximately 85%) of lung cancer cases. Patients with localized disease can be cured through surgery, but only 20 % are operable.For the majority of patients with advanced disease, palliative cytotoxic chemotherapy remains the recommended therapy. Chemotherapy prolongs survival and improves quality of life.
The recommended first-line therapy is 4-6 courses of a platinum in combination with a third generation compound (e.g. gemcitabine, vinorelbine, docetaxel, pemetrexed, paclitaxel). After first-line therapy, it has been recommended to observe the patients and offer second-line chemotherapy at disease progression.
Regimens for second-line therapy include docetaxel or pemetrexed monotherapy. Pemetrexed is less toxic and superior to gemcitabine in non-squamous NSCLC, whereas docetaxel is the recommended second-line therapy in squamous cell carcinoma.
The results of the studies of maintenance pemetrexed therapy are encouraging; the observed survival benefit is clinically relevant and relatively large considering the poor survival in patients with advanced NSCLC. Furthermore, pemetrexed appears to be well tolerated. There are, however, several limitations to the studies that have been conducted: Relatively few elderly patients and no PS 2 patients were enrolled - and not all patients on the control-arms received pemetrexed at progression.
The overall aim of this study is to investigate whether immediate maintenance pemetrexed therapy prolongs survival compared to observation and pemetrexed therapy at progression in patients with advanced NSCLC. Furthermore, it will be explored whether patients with 'performance status' 2 and elderly ≥ 70 years tolerate and benefit from maintenance therapy; and what characteristics and blood biomarkers are associated with sensitivity and tolerability of such therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
In previous studies without maintenance therapy, median overall survival (OS) for performance status (PS) 0-1 patients has been approximately 9 months, corresponding to 6 months from randomization in this study. We consider an improvement in overall survival of two months to be the minimum difference that will lead to routine use of maintenance pemetrexed in Norway. To demonstrate an improvement in median overall survival from 6 to 8 months with an α =0.05 and β =0.20, 198 evaluable patients are required on each arm. We expect a drop-out rate of maximum 10 %, and therefore intend to randomize a total of 436 patients (PS 0-1) - of which we expect 150 to be 70 years or older.
Sample size is calculated on PS 0-1 patients only. In addition, PS 2 patients will be randomized until the required number of PS 0-1 patients have been accrued. We estimate that a total of 100 PS 2 patients will be enrolled - sufficient for hypothesis-generating analyses of the benefit of maintenance therapy in elderly and PS 2 patients.
Based on experience from our previous studies we estimate that approximately 30% of patients will not complete or progress during induction chemotherapy; or be ineligible due deterioration of PS. Consequently, we need to include approximately 765 patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: maintenance pemetrexed maintenance pemetrexed immediately after induction chemotherapy |
Drug: maintenance pemetrexed
500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
Other Names:
|
| Active Comparator: pemetrexed at progression observation and pemetrexed therapy at disease progression |
Drug: pemetrexed at progression
500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
Other Names:
|
Outcome Measures
Primary Outcome Measures
- overall survival [2 years]
All patients will be followed until death of any reason - assessed up to 24 months after inclusion in the study.
Secondary Outcome Measures
- progression free survival [2 years]
From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.
- Toxicity [2 years]
All patients will be followed for 2 years (or until 1 month after the end of study therapy if study therapy is discontinued before 2 years after study inclusion).
- Health related quality of life [2 years]
All patients will be followed until discontinuation of study therapy - up to 24 months after inclusion in the study.
Other Outcome Measures
- Overall survival in elderly and PS 2 patients [2 years]
All patients will be followed until death of any reason - assessed up to 24 months after inclusion in the study.
- Associations between clinical characteristics and blood biomarkers - and outcomes of therapy [2 years]
All patients will be followed until death of any reason - assessed up to 24 months after inclusion in the study.
- Toxicity in elderly and PS 2 patients [2 years]
All patients will be followed for 2 years (or until 1 month after the end of study therapy if study therapy is discontinued before 2 years after study inclusion).
- Health related quality of life in elderly and PS 2 patients [2 years]
All patients will be followed until discontinuation of study therapy - up to 24 months after inclusion in the study.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Measureable disease according to the RECIST 1.1
-
Previous radiotherapy is acceptable provided there are measurable, previously not irradiated lesions present
-
Histologically or cytologically confirmed non-squamous non-small cell lung cancer
-
Stage IIIB ineligible for curative therapy or stage IV disease
-
ECOG Performance 0-2
-
Adequate organ function defined as:
-
Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN), or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy.
-
Total serum bilirubin ≤ 1.5 x ULN
-
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
-
Platelets ≥ 100 x 109/L
-
Creatinine clearance > 45 ml/min
-
Able to discontinue NSAIDs and ASA if reduced renal function
-
All fertile patients should use safe contraception
-
Written informed consent
Exclusion Criteria:
-
prior systemic therapy for advanced non-small-cell lung cancer (including EGFR-TKI). Previous chemotherapy (e.g. adjuvant after surgery or for other cancer) is allowed if ≥ 3 months since the last course was administered.
-
activating EGFR-mutation or ALK-translocation detected
-
serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study treatment
-
conditions - medical, social, psychological - which could prevent adequate information and follow-up
-
clinically active cancer other than NSCLC
-
known hypersensitivity or contraindications for the study drugs (vinorelbine, carboplatin, pemetrexed, B12, folate)
-
pregnant or lactating women
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | St Olavs Hospital | Trondheim | Norway |
Sponsors and Collaborators
- Norwegian University of Science and Technology
- St. Olavs Hospital
Investigators
- Principal Investigator: Bjørn H Grønberg, MD PhD, Norwegian University of Science and Technology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2013/645
- 2013-001237-41